Ypsomed has agreed to sell its diabetes care business for up to CHF 420 million (approximately $509 million) to TecMed, a deal it said will help it focus on strengthening its position in the market for subcutaneous self-injection solutions for pharmaceutical and biotech companies.
Ypsomed is selling Ypsomed Diabetes Care AG, including the relevant subsidiaries, the patch pump development activities and related rights to TecMed. The transaction is expected to close in the second half of 2025, and Ypsomed said the sale proceeds will finance the expansion of the injection system business.
TecMed will combine Ypsomed tube pump system mylife Loop, including the mylife YpsoPump and the AID solution mylife CamAPS FX, with its patch pump program to create a global diabetes care company.
The combined company will have its new headquarters in Burgdorf with working space for around 300 employees. Approximately 200 employees currently working in Solothurn will move to Burgdorf later this year.
At the same time, Ypsomed is investing in two new production halls, a new tool shop, and a conference center at the Solothurn site, which will also be accessible to the public. By selling the pen needle manufacturing to the Italian company MTD and ending contract manufacturing for Sanofi, additional production capacities for the growing autoinjector business will be added at the Solothurn site.
